Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch-Reference-Cited by-同舟云学术

Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch

Published:2017-02-27 Issue:2 Volume:10 Page:84-92
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical And Translational Science

Author:

Scheerens H¹,Malong A¹,Bassett K¹,Boyd Z¹,Gupta V¹,Harris J¹,Mesick C¹,Simnett S¹,Stevens H²,Gilbert H¹,Risser P¹,Kalamegham R¹,Jordan J²,Engel J²,Chen S²,Essioux L³,Williams JA¹

Affiliation:

1. Genentech Inc.; San Francisco California USA

2. Roche AG; Basel Switzerland

3. Pharmaceutical Sciences; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Ltd; Basel Switzerland

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cts.12455/fullpdf

Reference23 articles.

1. FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet] 2016

2. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome;Lotvall;J. Allergy Clin. Immunol,2011

3. Severe asthma: from characteristics to phenotypes to endotypes;Wenzel;Clin. Exp. Allergy,2012

4. Trastuzumab-mechanism of action and use in clinical practice;Hudis;N. Engl. J. Med,2007

5. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial;Rosenberg;Lancet,2016

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring single-cell RNA sequencing as a decision-making tool in the clinical management of Fuchs’ endothelial corneal dystrophy;Progress in Retinal and Eye Research;2024-09

2. CRISPR/Cas9-mediated knockout strategies for enhancing immunotherapy in breast cancer;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-06-22

3. Programmed Death Ligand 1 (PD-L1) Expression in Lymphomas: State of the Art;International Journal of Molecular Sciences;2024-06-11

4. Preexisting antibody assays for gene therapy: Considerations on patient selection cutoffs and companion diagnostic requirements;Molecular Therapy - Methods & Clinical Development;2024-03

5. New regulatory thinking is needed for AI-based personalised drug and cell therapies in precision oncology;npj Precision Oncology;2024-01-30